In layman terms, Advanced Proteome has developed a proprietary approach for streamlining the production and targeted delivery of anti-cancer drugs to cancerous tumors. The benefit is that a cancer patient’s tumor cells are destroyed selectively, sparing healthy cells.
Also of benefit is that the proprietary process we are implementing is versatile and potentially universal in its applications to such targeted therapies. They are expected to be easier to produce and to exhibit greater potency, higher specificity and lower toxicity than current-day therapies that do destroy a cancer patient’s normal healthy cells.
Targeted therapies, such as Advanced Proteome’s approach, home in on cancer cells thereby avoiding the nasty side effects of traditional chemotherapeutics.
Advanced Proteome’s approach, in addition, exploits universal features of antibodies, thereby simplifying and standardizing, as well as accelerating the process of creating new antibody-drug conjugates.
Because of the benefits of our innovative approach over traditional approaches, we expect to profoundly impact the markets for anti-cancer therapeutics.